Literature DB >> 25045154

Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features.

Jacqueline G O'Leary1, S Michelle Shiller, Christopher Bellamy, Michael A Nalesnik, Hugo Kaneku, Linda W Jennings, Kumiko Isse, Paul I Terasaki, Göran B Klintmalm, Anthony J Demetris.   

Abstract

Acute antibody-mediated rejection (AMR) occurs in a small minority of sensitized liver transplant recipients. Although histopathological characteristics have been described, specific features that could be used (1) to make a generalizable scoring system and (2) to trigger a more in-depth analysis are needed to screen for this rare but important finding. Toward this goal, we created training and validation cohorts of putative acute AMR and control cases from 3 high-volume liver transplant programs; these cases were evaluated blindly by 4 independent transplant pathologists. Evaluations of hematoxylin and eosin (H&E) sections were performed alone without knowledge of either serum donor-specific human leukocyte antigen alloantibody (DSA) results or complement component 4d (C4d) stains. Routine histopathological features that strongly correlated with severe acute AMR included portal eosinophilia, portal vein endothelial cell hypertrophy, eosinophilic central venulitis, central venulitis severity, and cholestasis. Acute AMR inversely correlated with lymphocytic venulitis and lymphocytic portal inflammation. These and other characteristics were incorporated into models created from the training cohort alone. The final acute antibody-mediated rejection score (aAMR score)--the sum of portal vein endothelial cell hypertrophy, portal eosinophilia, and eosinophilic venulitis divided by the sum of lymphocytic portal inflammation and lymphocytic venulitis--exhibited a strong correlation with severe acute AMR in the training cohort [odds ratio (OR) = 2.86, P < 0.001] and the validation cohort (OR = 2.49, P < 0.001). SPSS tree classification was used to select 2 cutoffs: one that optimized specificity at a score > 1.75 (sensitivity = 34%, specificity = 86%) and another that optimized sensitivity at a score > 1.0 (sensitivity = 81%, specificity = 71%). In conclusion, the routine histopathological features of the aAMR score can be used to screen patients for acute AMR via routine H&E staining of indication liver transplant biopsy samples; however, a definitive diagnosis requires substantiation by DSA testing, diffuse C4d staining, and the exclusion of other insults.
© 2014 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25045154      PMCID: PMC4412307          DOI: 10.1002/lt.23948

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  41 in total

1.  Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells.

Authors:  F Kissmeyer-Nielsen; S Olsen; V P Petersen; O Fjeldborg
Journal:  Lancet       Date:  1966-09-24       Impact factor: 79.321

2.  Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model.

Authors:  K Nakamura; N Murase; M J Becich; T Furuya; S Todo; J J Fung; T E Starzl; A J Demetris
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

3.  Grading of cellular rejection after orthotopic liver transplantation.

Authors:  S Datta Gupta; M Hudson; A K Burroughs; R Morris; K Rolles; P Amlot; P J Scheuer; A P Dhillon
Journal:  Hepatology       Date:  1995-01       Impact factor: 17.425

4.  Sinusoidal C4d deposits in liver allografts indicate an antibody-mediated response: diagnostic considerations in the evaluation of liver allografts.

Authors:  Tomasz Kozlowski; Kenneth Andreoni; John Schmitz; Paul Hideo Hayashi; Volker Nickeleit
Journal:  Liver Transpl       Date:  2012-06       Impact factor: 5.799

5.  Evidence for hyperacute rejection of human liver grafts: The case of the canary kidneys.

Authors:  Thomas E Starzl; Anthony J Demetris; Satoru Todo; Yoogoo Kang; Andreas Tzakis; Rene Duquesnoy; Leonard Makowka; Barbara Banner; Waldo Concepcion; Kendrick A Porter
Journal:  Clin Transplant       Date:  1989       Impact factor: 2.863

6.  Liver transplantation across ABO blood groups.

Authors:  R D Gordon; S Iwatsuki; C O Esquivel; A Tzakis; S Todo; T E Starzl
Journal:  Surgery       Date:  1986-08       Impact factor: 3.982

7.  Evidence for an immune response to HLA class I antigens in the vanishing-bileduct syndrome after liver transplantation.

Authors:  P T Donaldson; G J Alexander; J O'Grady; J Neuberger; B Portmann; M Thick; H Davis; R Y Calne; R Williams
Journal:  Lancet       Date:  1987-04-25       Impact factor: 79.321

8.  Influence of positive lymphocyte crossmatch and HLA mismatching on vanishing bile duct syndrome in human liver allografts.

Authors:  K P Batts; S B Moore; J D Perkins; R H Wiesner; P M Grambsch; R A Krom
Journal:  Transplantation       Date:  1988-02       Impact factor: 4.939

9.  Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: studies toward further defining their significance.

Authors:  R Mañez; R H Kelly; M Kobayashi; S Takaya; O Bronsther; D Kramer; R J Duquesnoy; Y Iwaki; J J Fung; T E Starzl
Journal:  Hepatology       Date:  1995-05       Impact factor: 17.425

Review 10.  Antibody-mediated rejection in the liver allograft.

Authors:  Stefan G Hübscher
Journal:  Curr Opin Organ Transplant       Date:  2012-06       Impact factor: 2.640

View more
  16 in total

Review 1.  Enhancing the Value of Histopathological Assessment of Allograft Biopsy Monitoring.

Authors:  Michelle A Wood-Trageser; Andrew J Lesniak; Anthony J Demetris
Journal:  Transplantation       Date:  2019-07       Impact factor: 4.939

2.  Endothelial Cell-Derived Interleukin-18 Released During Ischemia Reperfusion Injury Selectively Expands T Peripheral Helper Cells to Promote Alloantibody Production.

Authors:  Lufang Liu; Caodi Fang; Whitney Fu; Bo Jiang; Guangxin Li; Lingfeng Qin; Jacob Rosenbluth; Gavin Gong; Catherine B Xie; Peter Yoo; George Tellides; Jordan S Pober; Dan Jane-Wit
Journal:  Circulation       Date:  2019-11-20       Impact factor: 29.690

Review 3.  ABO-compatible liver allograft antibody-mediated rejection: an update.

Authors:  Anthony J Demetris; Adriana Zeevi; Jacqueline G O'Leary
Journal:  Curr Opin Organ Transplant       Date:  2015-06       Impact factor: 2.640

Review 4.  [Chronic rejection: Differences and similarities in various solid organ transplants].

Authors:  H Suhling; J Gottlieb; C Bara; R Taubert; E Jäckel; M Schiffer; J H Bräsen
Journal:  Internist (Berl)       Date:  2016-01       Impact factor: 0.743

Review 5.  Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  J Clin Invest       Date:  2017-06-12       Impact factor: 14.808

Review 6.  The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejection.

Authors:  Kimberly A Thomas; Nicole M Valenzuela; Elaine F Reed
Journal:  Trends Mol Med       Date:  2015-03-20       Impact factor: 11.951

Review 7.  Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation.

Authors:  Antonio Cuadrado; David San Segundo; Marcos López-Hoyos; Javier Crespo; Emilio Fábrega
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

8.  Exploring pre-surgery donor-specific antibodies in the context of organ shortage in liver transplant.

Authors:  Savio G Barreto; Mark E Brooke-Smith; Eu Ling Neo; Paul Dolan; Richard Leibbrandt; Tim Emery; Robert Carroll; Alan Wigg; John W Chen
Journal:  Langenbecks Arch Surg       Date:  2019-11-20       Impact factor: 3.445

Review 9.  The Role of Humoral Alloreactivity in Liver Transplantation: Lessons Learned and New Perspectives.

Authors:  Elaine Y Cheng
Journal:  J Immunol Res       Date:  2017-01-09       Impact factor: 4.818

10.  Rituximab Desensitization in Liver Transplant Recipients With Preformed Donor-specific HLA Antibodies: A Japanese Nationwide Survey.

Authors:  Nobuhisa Akamatsu; Kiyoshi Hasegawa; Seisuke Sakamoto; Hideki Ohdan; Ken Nakagawa; Hiroto Egawa
Journal:  Transplant Direct       Date:  2021-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.